Table 3 Adverse events in in older patients treated with immune checkpoint inhibitors
Age < 70 (n = 70) | Age ≥ 70 (n = 25) | |||||
|---|---|---|---|---|---|---|
Grade 0 | Grade 1 or 2 | Grade 3 to 5 | Grade 0 | Grade 1 or 2 | Grade 3 to 5 | |
Any adverse event (%) | 1 (1.4) | 51 (72.9) | 18 (25.7) | 1 (4.0) | 18 (72.0) | 6 (24.0) |
Anaemia (%) | 6 (8.6) | 47 (67.1) | 17 (24.3) | 3 (12.0) | 17 (68.0) | 5 (20.0) |
Leukopenia (%) | 32 (45.7) | 23 (32.9) | 15 (21.4) | 21 (84.0) | 2 (8.0) | 2 (8.0) |
Neutropenia (%) | 48 (68.6) | 10 (14.3) | 12 (17.1) | 20 (80.0) | 2 (8.0) | 3 (12.0) |
Thrombocytopenia (%) | 48 (68.6) | 15 (21.4) | 7 (10.0) | 18 (72.0) | 7 (28.0) | 0 (0.0) |
Infection (%) | 39 (55.7) | 22 (31.4) | 9 (12.9) | 18 (72.0) | 6 (24.0) | 1 (4.0) |
Bleeding (%) | 57 (81.4) | 11 (15.7) | 2 (2.9) | 24 (96.0) | 1 (4.0) | 0 (0.0) |
Nausea (%) | 57 (81.4) | 13 (18.6) | 0 (0.0) | 16 (64.0) | 9 (36.0) | 0 (0.0) |
Diarrhoea (%) | 64 (91.4) | 5 (7.1) | 1 (1.4) | 23 (92.0) | 1 (4.0) | 1 (4.0) |
Fatigue (%) | 60 (85.7) | 9 (12.9) | 1 (1.4) | 19 (76.0) | 6 (24.0) | 0 (0.0) |
Dermatitis (%) | 67 (95.7) | 3 (4.3) | 0 (0.0) | 22 (88.0) | 2 (8.0) | 1 (4.0) |
Fever (%) | 64 (91.4) | 6 (8.6) | 0 (0.0) | 23 (92.0) | 1 (4.0) | 1 (4.0) |
Cardiac disorders (%) | 55 (78.6) | 11 (15.7) | 4 (5.7) | 21 (84.0) | 4 (16.0) | 0 (0.0) |
Pneumonitis (%) | 64 (91.4) | 1 (1.4) | 5 (7.1) | 24 (96.0) | 0 (0.0) | 1 (4.0) |
Creatinine increase (%) | 54 (77.1) | 13 (18.6) | 3 (4.3) | 19 (76.0) | 5 (20.0) | 1 (4.0) |
Elevated ALT or AST concentrations (%) | 38 (54.3) | 30 (42.9) | 2 (2.9) | 18 (72.0) | 7 (28.0) | 0 (0.0) |
Cognitive disturbance (%) | 68 (97.1) | 2 (2.9) | 0 (0.0) | 25 (100.0) | 0 (0.0) | 0 (0.0) |
Sensory neuropathy (%) | 62 (88.6) | 8 (11.4) | 0 (0.0) | 24 (96.0) | 1 (4.0) | 0 (0.0) |
Hypothyroidism (%) | 45 (64.3) | 25 (35.7) | 0 (0.0) | 18 (72.0) | 7 (28.0) | 0 (0.0) |